TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System

Advancing Stent Design for Drug Delivery

The TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System is engineered specifically for consistent drug elution and impressive performance. Enhanced deliverability features allow access to the target lesion, because first you have to get there.

• Uniform stent geometry promotes even and consistent neointimal coverage
• Thin struts and enhanced stent delivery system improve deliverability
• Proven performance of paclitaxel supported by the rigor of theTAXUS clinical program

Engineered for Consistent Drug Distribution

Unique Uniform Cell Geometry

• Supports even drug delivery and distribution
• Provides uniform vessel coverage for arterial support
• Reduces gaps in drug concentration loaded on the stent

Three Customized Stent Models

• Allows for more consistent stent-to-artery coverage in varying anatomies
• Innovative hybrid cell design for support and flexibility

The TAXUS Liberté Stent’s Unique Design Results in Uniform Neointimal Coverage

• 25% more uniform neointimal coverage and improved stent apposition**
• Consistent low levels of neointimal volume

*Computer modeling of drug distribution uniformity in vascular tissue. Modeling results are for demonstration purposes only and may not necessarily be indicative of clinical performance. Testing completed by Boston Scientific Corporation. Data on file.
**As compared to the TAXUS® Express²™ Stent System. Data on file.

Enhanced Design for Deliverability

Thinner Stent Struts

• 27% thinner stent struts than the TAXUS® Express® Stent for greater flexibility and improved deliverability
• Conformable design for improved stent apposition

Reduced Stent Profile

• 6.1% reduction in stent profile over TAXUS® Express²™ Stent System
• Lowest tip profile (0.017")

Enhanced Stent Delivery System

• Improved tip design for greater flexibility and smooth tip-to-balloon transitions
• Improved trackability to navigate distal lesions
• New five wing fold design on workhorse and large models for a tighter rewrap

Proven Performance and the TAXUS Family Clinical Program

The safety and efficacy of paclitaxel and the Translute™ Polymer have been tested and proven extensively in robust pre-clinical, clinical and real-world applications.

Unique, multifunctional anti-restenotic effect of paclitaxel

• Stabilizes microtubules to inhibit smooth muscle cell migration and proliferation
• Unlike other anti-restenonic agents, paclitaxel is not dependent on blocking a specific pathway and helps inhibit cell migration and proliferation regardless of the cellular signaling process or pathway

Stable, durable and reliable Translute Polymer

• Vascular compatible and biocompatible
• Provides consistent and controlled dose release of paclitaxel

TAXUS clinical program built upon the proven performance of paclitaxel

Trust Your Own Experience…

The TAXUS® Stent family of products is built on long-term clinical outcomes and the proven performance of paclitaxel. Look to Boston Scientific’s TAXUS Drug-Eluting Stent family, implanted in over four million patients worldwide, for proven drug-eluting stent performance.

Device Illustration

1. 1.8/2.0F full length hypotube shaft
2. Tapered corewire
3. Bioslide™ hydrophilic coating
4. Pebax® distal shaft 2.7F
5. DynaLEAP™ balloon material provides controlled growth
6. Laser Bonded technology
7. Enhanced TrakTip™ with 0.017" lesion entry profile

1. Low profile (3.2F) proximal shaft
2. Polyamide proximal shaft
3. Variable stiffness PushCoil
4. Bioslide™ hydrophilic coating
5. Transitionless distal shaft 2.7F
6. DynaLEAP™ balloon material provides controlled growth
7. Laser Bonded technology
8. Tapered TrakTip™ with 0.017" lesion entry profile

TAXUS Liberté Coronary Stent System Size Matrix